Illinois is currently home to 2627 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Umbrella Study for Analysis of Data Related to Patients With Cancer
NCT06018753
Recruiting
This study is a multisite, minimal risk, non-interventional study using patient electronic health record data collected as part of standard of care to answer cohort-based research questions and create robust real-world data sets.
Gender:
ALL
Ages:
All
Trial Updated:
04/09/2025
Locations: Illinois Cancer Care, Peoria, Illinois
Conditions: Cancer
Register for Updates
SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial
NCT05831202
Recruiting
To establish the safety and effectiveness of the SEAL™ Saccular Endovascular Aneurysm Lattice system for the treatment of saccular intracranial aneurysms. The data from this study will be used to support a premarket approval (PMA) submission.
Gender:
ALL
Ages:
Between 22 years and 80 years
Trial Updated:
04/09/2025
Locations: Endeavor Health - Northwest Community Hospital, Arlington Heights, Illinois
Conditions: Intracranial Aneurysm
Register for Updates
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153
Recruiting
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/09/2025
Locations: University Retina and Macula Associates, PC, Oak Forest, Illinois
Conditions: Neovascular Age-related Macular Degeneration (nAMD)
Register for Updates
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
NCT05729373
Recruiting
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/09/2025
Locations: Uptown Research Institute, LLC, Chicago, Illinois
Conditions: Generalized Anxiety Disorder
Register for Updates
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
NCT05639543
Recruiting
The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/09/2025
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Alcohol Associated Hepatitis
Register for Updates
Alzheimer's Disease Neuroimaging Initiative 4
NCT05617014
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
04/09/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Mild Cognitive Impairment, Alzheimer Disease, Dementia
Register for Updates
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895
Recruiting
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Research Site, Elmhurst, Illinois
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018
NCT04590326
Recruiting
This study is researching an investigational drug called REGN5668. Participants will receive additional investigational drugs in combination with REGN5668. These additional drugs include cemiplimab or REGN4018 (with or without sarilumab). The main purposes of this study are to: * Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus * Look for signs that t... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
Register for Updates
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
NCT00198068
Recruiting
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
04/09/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Systemic Lupus Erythematosus, Antiphospholipid Syndrome
Register for Updates
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
NCT06244485
Recruiting
This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd ADC in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Advanced Solid Tumor
Register for Updates
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120
Recruiting
The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grfating (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grfating (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocar... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Register for Updates
A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:
NCT06676072
Recruiting
The objective of this clinical study is to demonstrate that ablation with the TactiFlex SE Ablation catheter, in conjunction with a compatible pulsed field ablation (PFA) and/or radio frequency (RF) generator, is safe and effective for the treatment of symptomatic, recurrent, drug refractory paroxysmal atrial fibrillation (PAF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Loyola University Medical Center, Maywood, Illinois
Conditions: Atrial Fibrillation (AF), Atrial Arrhythmia, Paroxysmal AF, Drug Refractory Paroxysmal Atrial Fibrillation
Register for Updates